Shattuck LabsShattuck Labs reported second-quarter 2026 results and Phase 1 clinical trial results for SL-325. The company plans to start the RECEPTIVE-CD1 Phase 2b Crohn’s disease trial in the third quarter of 2026, with primary endpoint data expected in the first half of 2028. R&D expenses rose to $11.7 million from $8.7 million a year earlier.
ABOUT
Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.
SCORING
Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.
DISCOVERY
Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.
For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.
